Global Humira Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Humira Market was valued at $9.6 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 5.1% CAGR, to an estimated market size of $12.3 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global Humira market encompasses the commercial sales and therapeutic application of the biologic drug adalimumab, including the original branded product and its biosimilar competitors. The scope covers treatments for autoimmune and inflammatory conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis, while excluding non-adalimumab TNF inhibitors.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Humira Market in the period 2025-30:
- The expiration of patent exclusivity in the United States has triggered a massive shift from a monopoly to a multi-competitor landscape.
- Aggressive price erosion is being driven by biosimilar manufacturers offering discounts ranging from 5% to 90% off the original list price.
- Pharmacy Benefit Managers (PBMs) and payers are increasingly removing branded Humira from formularies to mandate the use of lower-cost biosimilars.
- The emergence of interchangeable biosimilars is facilitating automatic substitution at the pharmacy level, significantly accelerating market share loss for the originator.
- AbbVie is actively transitioning its patient base to next-generation therapies like Skyrizi and Rinvoq to mitigate the impact of the adalimumab patent cliff.
- There is a notable specialty-specific adoption variance, where gastroenterologists are more willing to switch patients to biosimilars compared to more resistant dermatologists.
- The market is seeing a shift toward high-concentration formulations and citrate-free versions to improve patient comfort and maintain brand loyalty.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Branded Humira (Originator)
- Adalimumab Biosimilars